home / stock / ocup / ocup news

OCUP News and Press, Ocuphire Pharma Inc Com From 09/27/23

Stock Information
Company Name: Ocuphire Pharma Inc Com
Stock Symbol: OCUP
Market: NASDAQ
Website: ocuphire.com
Menu
OCUP OCUP Quote OCUP Short OCUP News OCUP Articles OCUP Message Board
Get OCUP Alerts

News, Short Squeeze, Breakout and More Instantly...
OCUP - Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI(TM) (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.,

FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders and ...
OCUP - Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences

FARMINGTON HILLS, Mich., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced tha...

OCUP - Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September

FARMINGTON HILLS, Mich., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced tha...

OCUP - Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

FARMINGTON HILLS, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that...
OCUP - Ocuphire Pharma GAAP EPS of -$0.24 beats by $0.03, revenue of $3.67M beats by $1.39M

2023-08-11 08:49:06 ET Ocuphire Pharma press release ( NASDAQ: OCUP ): Q2 GAAP EPS of -$0.24 beats by $0.03 . Revenue of $3.67M beats by $1.39M . As of June 30, 2023, Ocuphire had cash and cash equivalents of approximately $40.0 million. The Company has no debt...

OCUP - Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update

End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Million Expected to Fund Operations into 2025 Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire ...

OCUP - Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August

FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that...
OCUP - Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy End-of-Phase 2 meeting with FDA for APX3330 scheduled for Q4 2023 FARMINGTON HILLS, Mich., July 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage o...

OCUP - Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

FARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that...

OCUP - Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference

FARMINGTON HILLS, Mich., June 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H. Gonz...
Previous 10 Next 10